Oppenheimer set a $166.00 price target on Celgene (NASDAQ:CELG) in a research report released on Thursday, November 16th. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
CELG has been the subject of a number of other research reports. Cantor Fitzgerald set a $160.00 target price on Celgene and gave the stock a buy rating in a report on Thursday, July 27th. William Blair reissued an outperform rating on shares of Celgene in a report on Friday, October 20th. BMO Capital Markets reaffirmed an outperform rating and issued a $160.00 price objective (up previously from $152.00) on shares of Celgene in a report on Friday, July 28th. Leerink Swann reaffirmed a buy rating and issued a $156.00 price objective on shares of Celgene in a report on Friday, October 20th. Finally, Piper Jaffray Companies reaffirmed a neutral rating and issued a $133.00 price objective on shares of Celgene in a report on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have issued a buy rating and two have issued a strong buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $139.57.
Celgene (NASDAQ CELG) traded up $0.47 during trading on Thursday, hitting $102.61. The company’s stock had a trading volume of 5,470,354 shares, compared to its average volume of 4,764,378. The company has a market cap of $81,380.00, a price-to-earnings ratio of 15.96, a price-to-earnings-growth ratio of 0.79 and a beta of 1.77. Celgene has a twelve month low of $94.55 and a twelve month high of $147.17. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31.
Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.58 EPS. research analysts expect that Celgene will post 6.67 earnings per share for the current fiscal year.
In other news, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the transaction, the insider now directly owns 3,925 shares in the company, valued at $564,768.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gilla Kaplan sold 9,250 shares of the business’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the completion of the transaction, the director now owns 85,551 shares in the company, valued at $12,110,599.56. The disclosure for this sale can be found here. Insiders have sold 20,227 shares of company stock worth $2,843,956 over the last quarter. 0.95% of the stock is owned by company insiders.
Institutional investors have recently made changes to their positions in the company. Neuberger Berman Group LLC increased its holdings in shares of Celgene by 4.0% in the first quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock worth $229,553,000 after purchasing an additional 71,729 shares during the last quarter. Grisanti Capital Management LLC bought a new stake in Celgene during the second quarter worth approximately $3,616,000. Lincoln Capital Corp increased its stake in Celgene by 0.6% during the second quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock worth $3,971,000 after acquiring an additional 185 shares during the last quarter. RiverPoint Capital Management LLC increased its stake in Celgene by 3.1% during the second quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock worth $15,799,000 after acquiring an additional 3,680 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its stake in Celgene by 9.2% during the second quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock worth $83,344,000 after acquiring an additional 54,210 shares during the last quarter. Institutional investors and hedge funds own 80.17% of the company’s stock.
WARNING: “Celgene (CELG) Given a $166.00 Price Target at Oppenheimer” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/05/oppenheimer-holdings-inc-reiterates-166-00-price-target-for-celgene-corporation-celg.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.